Holen Sie sich die Stockscreener-App
2.98
8.31%
-0.27
Handel nachbörslich:
3.01
0.03
+1.01%
Agenus Inc Aktie (AGEN) Neueste Nachrichten
Are options traders betting on a big move in Agenus stock? - MSN
Why is Agenus (AGEN) down 9.6% since last earnings report? - MSN
Agenus Inc. (AGEN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report? - Yahoo Finance
AGEN Early Access Revenues Signal a New Path Ahead of Approval - TradingView
Is Agenus Stock a Hold Amid Valuation and Funding Risks? - Yahoo Finance
AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC - Yahoo Finance
Agenus Inc. (AGEN) Latest Press Releases & Corporate News - Yahoo Finance
Agenus Announces Virtual 2026 Annual Shareholders Meeting - Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - TMX Newsfile
Garo H. Armen of Agenus (NASDAQ: AGEN) receives 4,644-share stock salary grant - Stock Titan
AGEN Stock Price, Quote & Chart | AGENUS INC (NASDAQ:AGEN) - ChartMill
Agenus Inc.Common Stock (NQ: AGEN - FinancialContent
AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential? - TradingView
AGEN Technical Analysis | Trend, Signals & Chart Patterns | AGENUS INC (NASDAQ:AGEN) - ChartMill
How Agenus' Pipeline Progress Unlock Its Next Growth Phase - TradingView
Agenus: Weighing The Clinical Progress Against The Company's Cash (NASDAQ:AGEN) - Seeking Alpha
BOT+BAL Demonstrates Durable Immune Benefit in Advanced Melanoma – Agenus - Oncodaily
Agenus reports melanoma trial data for checkpoint therapy By Investing.com - Investing.com South Africa
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026 - BioSpace
AI model identifies colorectal cancer patients likely to respond - Investing.com UK
Agenus reports melanoma trial data for checkpoint therapy - Investing.com UK
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC - 01net
New melanoma drug combo sees 42% of patients alive at 2 years - Stock Titan
AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell? - TradingView
Agenus (AGEN) chief takes 4,540 common shares as salary - Stock Titan
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer - BioSpace
Agenus (AGEN) price target decreased by 32.61% to 15.81 - MSN
Agenus reports phase 1b liver cancer trial results By Investing.com - Investing.com India
Agenus (AGEN) Reports Phase 1b Results for Innovative Cancer Tre - GuruFocus
Agenus reports phase 1b liver cancer trial results - Investing.com UK
Agenus announces publication of Phase 1b BOT+BAL data - TipRanks
Agenus Announces Resignation of Principal Accounting Officer - TipRanks
Agenus Announces Publication of Phase 1b Botensilimab and Balstil - The National Law Review
Early drug combo yields responses in liver cancer after immunotherapy - Stock Titan
Agenus (AGEN) Principal Accounting Officer Austin Charette plans May 2026 exit - Stock Titan
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):